Viking Therapeutics (NASDAQ: VKTX) discloses VK2735 oral Phase 2 top-line data

Rhea-AI Filing Summary

Viking Therapeutics, Inc. filed a current report to highlight that, on August 19, 2025, it issued a press release announcing top-line results from its Phase 2 clinical trial of the oral tablet formulation of VK2735. The company furnished this press release as Exhibit 99.1 and clarified that the information provided under the Regulation FD disclosure section is being furnished rather than filed for liability purposes under securities laws.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000160767800016076782025-08-192025-08-19

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2025

Viking Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37355	46-1073877
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
9920 Pacific Heights Blvd, Suite 350
San Diego, California				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 858 704-4660

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		VKTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 19, 2025, Viking Therapeutics, Inc. issued a press release announcing top-line results from the Company’s Phase 2 clinical trial of the oral tablet formulation of VK2735. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished under this Item 7.01 (Regulation FD Disclosure) of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release, dated August 19, 2025.
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			VIKING THERAPEUTICS, INC.
Date:	August 19, 2025	By:	/s/ Brian Lian, Ph.D.
			Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

FAQ

What did Viking Therapeutics (VKTX) report in this 8-K filing?

Viking Therapeutics reported that it issued a press release on August 19, 2025 announcing top-line results from its Phase 2 clinical trial of the oral tablet formulation of VK2735, which is furnished as Exhibit 99.1.

What is the focus of Viking Therapeutics' Phase 2 trial mentioned for VKTX?

The filing states that the Phase 2 clinical trial evaluated the oral tablet formulation of VK2735, and the company announced top-line results from this study in a press release dated August 19, 2025.

How is the VK2735 Phase 2 press release included in Viking Therapeutics' 8-K?

The press release announcing top-line Phase 2 results for the oral tablet formulation of VK2735 is included as Exhibit 99.1 and is incorporated by reference in the current report.

Is the VK2735 Phase 2 information considered filed or furnished by Viking Therapeutics?

The company specifies that the information under Item 7.01, including the VK2735 Phase 2 press release, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced.

What exhibits did Viking Therapeutics (VKTX) attach to this 8-K?

Viking Therapeutics attached Exhibit 99.1, the press release dated August 19, 2025 about top-line Phase 2 VK2735 oral tablet results, and Exhibit 104, the cover page interactive data file in Inline XBRL format.

Who signed Viking Therapeutics' 8-K related to the VK2735 Phase 2 results?

The report was signed on behalf of Viking Therapeutics, Inc. by Brian Lian, Ph.D., President and Chief Executive Officer, as the principal executive officer, dated August 19, 2025.